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S. Nowag,a C. Frangville,b G. Multhaup,c J.-D. Marty,b C. Mingotaudb and R. Haag*aCore–shell and core–multishell nanocarriers were designed to
transport copper ions into cells. Herein, we present their synthesis and
physicochemical characterization and demonstrate the high inﬂuence
of their architectures on the loading and release of copper. Their low
toxicity may open a new way to balance the Cu-homeostasis in
neurodegenerative diseases.Copper (Cu) is an important biological cofactor for a number of
metalloenzymes and plays a key role inmany neurodegenerative
diseases,1 e.g., Alzheimer's disease (AD) and Parkinson's
disease. Particularly in the case of AD, disturbed homeostasis of
Cu leads to Cu deciency in the central nervous system (CNS).
Exogenous supply of Cu to the brain or CNS is one of the many
therapeutic approaches for addressing such deciency symp-
toms.2 For such a purpose, copper supply needs to bypass the
blood–brain barrier (BBB), which remains an unsolved
problem. Additionally, hyperperfusion in the AD brain leads to
decreased pH and inammatory processes in the CNS.3 All the
previous information helps in the design of smart nanocarriers
capable of performing Cu pH-triggered delivery across the BBB
(see Scheme 1). Hyperbranched polymers are promising repre-
sentatives of size controllable nanoscaﬀolds for transport and
drug delivery.4–7 In previous studies, hyperbranched poly-
(ethyleneimine) (PEI) has been used to develop Cu-encapsu-
lating nanocarriers.8 However, the poor biocompatibility due to
the presence of a large number of amine groups within PEI
limits the applications of such systems.nische Chemie, Freie Universita¨t Berlin,
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hemistry 2014To enhance biocompatibility, new core–multishell nano-
carriers with lower toxicity are required, e.g., functionalized,
hyperbranched polyglycerol (hPG). As a macromolecule, hPG
possesses a highly branched, globular dendritic structure of a
stable polyether scaﬀold and can be synthesized in a one-step
process.9 It exhibits similar properties to the well-used and FDA-
approved poly(ethylene glycol) (PEG), as it is non-toxic,
biocompatible, and not recognized by the immune system.10
Furthermore, modication of hPG is facile due to its large
number of peripheral hydroxyl groups. These functionalized
hPG can therefore be tailored to required properties such as
size, charge, or molecular weight, respectively.5,11–15 By the
attachment of shells, specialized architectures can be designed
for a wide variety of applications.16–20
Herein, we present the synthesis and properties of diﬀerent
modied hPG to develop biocompatible Cu-nanocarriers as
potential candidates in the therapy of Cu deciency disorders.
An hPG with a molecular weight of 10 kDa was selected for the
core in order to obtain nanocarriers of a few tens of nanometers.
Cu-binding ligands to be attached on hPG cores were then
reviewed to t in our specications. An example of Cu-binding
ligands are triazacyclononanes, which are known to form very
strong complexes with Cu that are irreversible under physio-
logical conditions.21 Clearly, copper-release into CNS acidic
conditions requires a weaker ligand for a pH-triggered release of
Cu. Tri- or dimethylethylene diamine moieties (TMEDA or
DMEDA, respectively) have been chosen as suitable candi-
dates.22 They form square planar bidentate Cu-complexes withScheme 1 Encapsulation and release of Cu ions in nanocarrier
systems.
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Fig. 1 Determination of the maximum loading of polymers by UV-
visible measurements. (a) Inﬂuence of the Cu : nanocarrier molar ratio
on the relative absorbance at 580 nm at room temperature with a
constant polymer concentration (80 mM). (b) Free metal ion concen-
tration depending on metal : CS molar ratios at room temperature
with CS concentration (6.2 mM).
Table 1 Properties of the CS, CMS and CRS structures
CS CMS CRS



























































































View Article Onlinemoderate interactions, which enable pH-dependent Cu release.
Furthermore, in order to increase the biocompatibility, to
enhance the retention time within blood circulation, or to hide
Cu from the environment, attachment of poly(ethylene glycol)
(PEG) chains in the outer sphere is required (see Scheme 1). Two
kinds of attachments were chosen to investigate the inuence of
structural design of nanocarriers on Cu-loading and release, as
well as their biocompatibility. Thus, hydrophilic PEG chains
were bound to amine building blocks leading to a core–multi-
shell structure (CMS) or directly to the hPG core for a core–
random shell architecture (CRS) (see Scheme 2). Finally, hPG
fully modied by TMEDA (CS structure in Scheme 2) was used as
a reference system.23
For the CMS synthesis, boc-protected DMEDA was rst
reacted with hPG to cover 70% of the hydroxyl groups of hPG's
surface. Aer deprotection, PEG1000-OM chains were attached to
the amino ligands. For the CRS, reaction of hPG with TMEDA
was controlled to yield a degree of functionalization on hPG's
surface of 70% (similar to that of CMS). The remaining mesy-
lates were then substituted by azides, which could be used in a
click reaction to attach propargylated PEG5000 (see character-
ization of CMS and CRS in the ESI†).
UV/vis spectroscopic experiments were then carried out to
determine the maximum Cu-loading capacity of the nanocarrier
in water. A stock solution of the polymer was mixed with an
increasing amount of Cu(II) to achieve diﬀerent Cu : polymer
molar ratios. Regardless of the polymer structure, an increase of
the absorbance at 580 nm was observed and should be related
to the d–d transition of copper ions complexed by amine
functions (see Fig. S1 in the ESI†). This demonstrated the
complexation of Cu inside the nanocarriers. Above a certain
concentration of copper, the absorbance at 580 nm became
constant and a new band around 800 nm related to aqueous
copper ions grew in size. This behavior is evidence for the
saturation of nanocarriers and that the later added copper ions
remained free in solution. The plot of the absorbance at 580 nm
for the increasing Cu : polymer ratio reveals that the CMSScheme 2 Structure and synthesis scheme of CS, CMS and CRS.
3916 | J. Mater. Chem. B, 2014, 2, 3915–3918structure can load more copper ions than the CRS polymer (see
Fig. 1a). The close t of these curves (see ESI†) leads to a more
quantitative evaluation of this maximum loading (see Table 1).
To check the loading capacity, we developed a second
method based on centrifugal ltration of the metal ion/polymer
solution. Titration of themetal ion was performed on the ltrate
using a well known spectroscopic method based on the Zincon
indicator (see Fig. S2 in the ESI†).24 As seen in Fig. 1b, the CS
system retains copper ions until a maximum loading of approx.
30. This is quite comparable with the direct evaluation by UV/vis
spectroscopy. Assuming a binding site of two ligands per
copper, one can estimate the maximum theoretical number of
sites per polymer and therefore the percentage of active sites. As
seen in Table 1, similar values were found for CS and CMS
structures. In contrast, the architecture of the CRS polymer is
less favorable for complexing Cu metal ions, which may be dueLoading capacitya 22  4 14  3 5  2
Percentage of
active sitesb




Sized (nm) 12/8 8/5 360e/6























a Determined by UV-visible spectroscopy (see text). b Ratio between the
experimental loading capacity and the maximum theoretical number of
sites per polymer estimated as half the number of ligand ethylene
diamine per polymer. c Determined by UV-visible spectroscopy (see
ESI). d Hydrodynamic radius (nanocarriers/Cu-loaded nanocarriers)
determined by DLS with an analysis in number from 80 mM
nanocarrier solutions. e Aggregation. f Determined on human
neuroblastoma cell line SH-SY5Y.
This journal is © The Royal Society of Chemistry 2014
Fig. 2 %Cu-release based on the relative absorbance at 580 nm of the
CMS or CRS polymer (80 mM) in Britton Robinson Buﬀers, 0.1 M NaCl at
37 C.



























































































View Article Onlineto the higher steric hindrance from the PEG-chains attached
between TMEDA-ligand units as well as from the aggregation of
CRS. The binding kinetics were fast and equilibrium was
reached only aer a few minutes (see Fig. S1 in the ESI†). All
these results indicated a behavior highly related to the archi-
tecture of the nanocarrier.
Aer addition of copper ions into a polymer solution,
reaching the equilibrium was a slower process for CRS than
CMS or CS (see Table 1). This may be partially due to the PEG
layer (larger in CRS than in CMS), which should have decreased
the accessibility of ions toward the ligand shell.
The ability for such structures to interact with other ionsmay
be providential for the delivery of copper in a controlled
manner. To evaluate such a possibility, a large excess of
diﬀerent ions (Ca, Mg, Mn, Co, Zn, Ni) was added to Cu-loaded
nanocarrier solutions (see Fig. S6 in the ESI†). None of the metal
ions were able to displace copper ions from the hyperbranched
structures.
Moreover, no direct complexation could be evidenced for
zinc ions, another ion of interest in the case of AD,25 as shown in
Fig. 1b. Thus, the obtained nanocarriers were of special interest
for the specic complexation and delivery of copper.
Blood clearance for molecules below 60 kDa and 6 nm is
fast, while bigger particles remain longer in the blood.26,27
However, particles bigger than 200 nm are likely renally
excreted.28 Since size also has a big impact on the perme-
ability of the BBB of substances,29–31 the size of the empty and
Cu-loaded nanocarriers was investigated by dynamic light
scattering (see Fig. S4 in the ESI†). Empty nanocarriers in
solution as a unimer were found to have a hydrodynamic
diameter close to 10 nm (see Table 1). When CMS was only in
the form of unimer, CS and CRS nanocarriers were more or
less present as polydisperse aggregates in solutions (Rh above
100 nm). When Cu was stabilized inside nanocarriers, a
signicant decrease of the aggregation and a slight change in
the size of the unimer were observed. Thus, the nanocarriers
presented here having molecular weights above 80 kDa and
diameters d $ 8 nm are in the right range for application as a
delivery system. However, permeation through the BBB might
be critical, since it has been postulated that most molecules
bigger than 400 Da are not able to pass the BBB.29 On the other
hand, it was observed that the ability to cross the BBB is much
higher for NPs with cationic character.30–32 Due to this, zeta
potentials of empty and Cu-loaded nanocarriers were studied
at pH values ranging from 7 to 3 in buﬀer solution. At pH 7,
the zeta potential of empty CS was found to be 30  9 mV. As
expected, graing of PEG chains induced a signicant
decrease of zeta potential that remained slightly positive for
both CRS (+13.9  0.8 mV) and CMS (+9.2  1.0 mV) (see
Fig. S5 in the ESI†). Partial protonation of amine groups may
have been responsible for this observation. Therefore, the
highest zeta potentials were measured at pH 3 due to the
increase of the protonation level at lower pH. Interestingly,
the surface charge at all the pH values did not signicantly
evolve when Cu ions were stabilized inside the nanocarriers.
Therefore, these positively charged nanocarriers have high
potential to cross the BBB.This journal is © The Royal Society of Chemistry 2014To prove whether nanocarriers were able to release copper
ions at low pH, UV/vis spectroscopy experiments were performed.
Cu-loaded nanocarriers were transferred in Britton Robinson
universal buﬀer aliquots with pH values from 8 to 2 and the
absorbance was monitored (see Fig. S3 in the ESI†). Fig. 2 shows
the percentage of Cu-release as a function of pH. As a result, Fig. 2
shows that CRS nanocarriers continuously released Cu with
decreasing pH. This prole of release highlights the weakness of
these nanocarriers due to the random architecture as discussed
above and might be too prompt, since the release already started
at pH 7. For application in biological systems a controlled release
is therefore not possible presumably due to Cu leakage before the
required target was reached. On the other hand, Cu-complexes'
integrity was retained in CS and CMS structures until lower pH
values. This indicates a stronger Cu binding in this architecture
whichmakes it a good candidate for carrying its entire load to the
target, aer which a sharp and fast Cu release could occur
according to Fig. 2 and kinetics data (see Fig. S3 in the ESI†).
The toxicity of Cu-loaded and empty nanocarriers in human
neuroblastoma (SH-SY5Y) cells was then investigated by MTT
assay (see experimental procedures in the ESI†). The IC50 value
of CRS was found to be 22.4 g L1, which was much higher and
therefore less toxic than CMS (IC50 ca. 415 mg L
1). It is known
that long PEG-chains lead to higher biocompatibility.33 Hence,
we assume that CRS with longer mPEG-chains shows less
toxicity than CMS, i.e., shielding of the amino ligands by mPEG-
chains determines the toxicity of the cargo in living cells. Both
nanocarriers in the present study were less toxic than the
previously described PEI-based CMS8 which supported our
earlier assumption that the hPG-based nanocarrier has a higher
compatibility than nanocarriers with a PEI core. Investigation
on the toxicity of Cu-loaded nanocarriers showed the same
result for CMS as for empty particles regarding the nanocarrier
concentration (IC50 [Cu : CMS ¼ 15 : 1] ¼ 415 mg L1). In
contrast, the cytotoxicity of Cu-loaded CRS increased to IC50
[Cu : CRS ¼ 5 : 1] ¼ 2.9 g L1 in comparison to unloaded CRS.
Regarding the Cu concentration, however, Cu-loaded CMS was
in the same range as Cu : CRS in terms of cytotoxicity (see Table
1). Both nanocarriers could reduce the toxicity of Cu by a factor
of 7.8 The compatibility at high loading is especially of impor-
tance for in vivo applications when a high local concentration of
Cu is required. According to these results, it seems that CMS is a
better candidate for the treatment of Cu deciency disorders.J. Mater. Chem. B, 2014, 2, 3915–3918 | 3917




























































































By designing new core–shell polymeric structures, we were able
to obtain nanocarriers that had a high binding aﬃnity for
copper ions and were able to release these ions at low pH. We
demonstrate that the exact architecture of the core–shell system
is a paramount parameter to control the maximum loading, the
strength of complexation, and the release prole of copper into
the solution. The CMS structure proved to be the most prom-
ising structure for Cu complexation and release. The CMS
structure will be studied to estimate its transport through the
BBB and tested in vivo for the release of copper.
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